The Million‑Patient Question: Is Eupraxia’s EP‑104GI Ready To Turn EoE Endoscopy Into A Business Model? -( $EPRX $SNY $XBI ) by John F. Heerdink, Jr. July 30, 2026 Read more The Esophagus Economy: How EP‑104GI Could Reshape EoE Treatment—and Eupraxia’s Valuation -( $EPRX $REGN $SNY ) by John F. Heerdink, Jr. July 20, 2026 Read more Cash, Catalysts and Credentials: Why Agenus and Eupraxia Are Starting to Screen In -( $AGEN $EPRX $XBI ) by John F. Heerdink, Jr. July 13, 2026 Read more Eupraxia’s Board Gets A Major Upgrade: Why EPRX Is Suddenly On Grown‑Up Biotech Lists -( $EPRX $IBB $SNY $XBI ) by John F. Heerdink, Jr. July 7, 2026 Read more The Immune System Strikes Back: Why Biogen’s M&A Spree and Eupraxia’s Trial Progress Deserve a Place On Your Radar -( $APLS $BIIB $EPRX ) by John F. Heerdink, Jr. July 3, 2026 Read more Biologics, Bulls, and Billion‑Dollar Plus Bets: AbbVie’s Immunology $10.9B ‘Durability’ Shopping Spree Explained -( $ABBV $APGE $EPRX $REGN $SNY ) by John F. Heerdink, Jr. June 22, 2026 Read more Biologics, Blister Bulls, EOE and Yearly Shots: Why Sanofi and Eupraxia Belong on Every Immunology Watchlist -( $EPRX $REGN $SNY ) by John F. Heerdink, Jr. June 19, 2026 Read more Wall Street Rallies Into SpaceX’s Historic Listing as World Cup 2026 Supercharges Global Streaming Demand -( $AMWL $DIA $EPRX $MODD QQQ $SPY $SPCX Rise!) by John F. Heerdink, Jr. June 12, 2026 Read more June 8, 2026 – AI Stocks Roar Back: Chip Rally Lifts Nasdaq as Wall Street Buys the Dip -( $AMWL $EPRX $HPP $INTG $MODD $MRVL $NOK $NVDA $TSLA Rise!) by John F. Heerdink, Jr. June 8, 2026 Read more June 5, 2026 – Strong Jobs, Weak Knees: How One Print Put Growth Stocks Back in Their Place This Week -( $ABM $COO $HPP $MCD $SOAR Rise!) by John F. Heerdink, Jr. June 5, 2026 Read more Read more
